Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T12:50:32.427Z.
Consensus retrieved: unavailable. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T12:50:32.427Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 83c64da899843448fde498cf5e629ee28b7cf55c7878198a0aebccb75d14602d
FORWARD PE RATIO
N/A
Aspire Biopharma Holdings, Inc.
Market Cap
$1.02M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | $1.02M | N/A |
| Clearmind Medicine Inc. (CMND)vs › | $1.11M | N/A |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.14M | N/A |
| Decoy Therapeutics Inc. (DCOY)vs › | $888387.00 | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $885939.00 | N/A |
| Bone Biologics Corporation (BBLG)vs › | $878396.00 | N/A |
| IM Cannabis Corp. (IMCC)vs › | $1.17M | N/A |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $787624.00 | N/A |
| CDT Equity Inc. (CDT)vs › | $707297.00 | N/A |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.36M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus fiscal-year EPS
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
